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y 6, 2013.his study hypothesized that right ventricular stroke work index (RVSWI) and pulmonary capacitance (PC) would
increase after treatment for pulmonary arterial hypertension (PAH) and that prostanoids would have a stronger
effect than oral therapy.Background Right ventricular (RV) function is a major determinant of outcome in patients with PAH. Little is known about the
response of RV function or its hemodynamic determinants to PAH-speciﬁc therapy.Methods We reviewed hemodynamic and health data on 58 patients from an institutional registry and analyzed changes in
hemodynamic status between diagnostic and ﬁrst repeat catheterization after initiation of therapy for PAH.Results The RVSWI and PC increased signiﬁcantly after therapy (p ¼ 0.007 and p ¼ 0.02, respectively). Improvement in RV
function was limited to patients treated with prostanoid-only therapy (p ¼ 0.04); no improvement was found in
patients treated with oral therapy (p ¼ 0.25). Patients with the poorest baseline RV function (lowest tertile) had the
greatest improvement post-therapy (p ¼ 0.005 and p < 0.001 vs. middle and highest tertiles). The major
determinant of RVSWI was change in stroke volume (rs ¼ 0.54, p < 0.001), indicating RVSWI is an accurate
reﬂection of RV function.Conclusions Right ventricular function improves after therapy with regimens including prostanoids but not oral-only regimens.
Patients with the least compensated RV function at diagnosis might derive the most beneﬁt from therapy. Larger
studies are needed to determine whether changes in RVSWI after therapy are associated with outcomes. (J Am
Coll Cardiol HF 2013;1:300–7) ª 2013 by the American College of Cardiology FoundationPulmonary arterial hypertension (PAH) is an incurable disease
characterized by progressive pulmonary vascular obliteration,
right ventricular (RV) failure, and death (1). Evidence suggests
that outcomes in PAH more closely mirror changes in RV
function than improvement in pulmonary hemodynamic status
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13; revised manuscript received May 6, 2013,PAH therapy on RV function might occur (3), but differences
among treatment regimens have not been studied. Availability
of an accurate measure of RV function at the time of cathe-
terization and knowledge of which medications are likely to
improve RV function might inﬂuence clinician choice of
therapy.
Conventional hemodynamic markers of RV function such
as right atrial pressure (RAP), cardiac output (CO), and
pulmonary pressure (PAP) can be integrated into a measure
of RV function, the right ventricular stroke work index
(RVSWI). Lower RVSWI is associated with worse outcome
in PAH, left ventricular failure, and left ventricular assist
device patients (5–7). Invasive hemodynamic status can also be
used to measure pulmonary capacitance (PC), a measure of
vascular resistance and elastic recoil. Depressed PC is a strong
prognostic indicator of adverse outcome in idiopathic PAH
(IPAH) (8). We have previously shown that RVSWI and PC
are prognostic indicators in a cohort of familial (FPAH) and
idiopathic pulmonary arterial hypertension (IPAH) (9).
However, the effect of different PAH-speciﬁc therapies onRV
function and PC has not been studied.
Abbreviations
and Acronyms
CO = cardiac output
FPAH = familial pulmonary
arterial hypertension
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301We studied the effect of therapy for PAH on RVSWI and
PC from the time of diagnostic catheterization to theﬁrst repeat
right heart catheterization (RHC). We hypothesized that RV
function and PCwould improve in response to therapy and that
prostanoids would have a stronger effect than oral therapy.HR = heart rate
IPAH = idiopathic pulmonary
arterial hypertension
mPAP = mean pulmonary
artery pressure
NYHA = New York Heart
Association
PAH = pulmonary arterial
hypertension
PC = pulmonary capacitance
PVR = pulmonary vascular
resistance
PWP = pulmonary wedge
pressure
RAP = right atrial pressure
RHC = right heart
catheterization
RV = right ventricle/
ventricular
RVSWI = right ventricular
stroke work index
SV = stroke volume
WU = Wood units
6MWD = 6-minute walk
distanceMethods
Study population. Data for this study were retrospectively
analyzed from an institutional registry. Patients in this study are
consecutive patients seen in the Vanderbilt University Center for
Pulmonary Vascular Disease and enrolled in the Vanderbilt
Pulmonary Hypertension Research Cohort (VPHRC). The
VPHRC also includes patients evaluated at outside institutions,
but only patients seen at Vanderbilt were included in this study.
Cases were restricted, to avoid confounding by treatment era, to
those with diagnostic hemodynamic and clinical data between
January 1, 1996 (when intravenous prostaglandins became
commercially available) and March 1, 2011.
The diagnosis of PAH was made by experienced physi-
cians according to consensus guidelines (10), including mean
pulmonary artery pressure (mPAP) 25 mmHg, pulmonary
vascular resistance (PVR) >3 wood units (WU), and
pulmonary wedge pressure (PWP) 15 mm Hg. Only
patients with IPAH, FPAH, and connective tissue disease-
associated PAH were included in the analysis. Patients were
diagnosed with FPAH if they had at least 1 other family
member within their bloodline conﬁrmed with PAH.
Only patients who were treatment-naïve at the time of
evaluation were included. Treatment regimens were catego-
rized as prostanoid (intravenous or inhaled), oral (mono-
therapy or in combination),mixed prostanoid and oral therapy,
and vasodilator (calcium channel blocker)-responsive. For
purposes of analysis, vasodilator-responsive patients were not
included in the oral therapy group, given the well-recognized
favorable hemodynamic response in this group (11).
Hemodynamic status. Heart rate (HR), RAP, PAP
(mean, systolic, and diastolic), PWP, and CO were recorded
from the diagnostic catheterization of the patient. Cardiac
index, PVR, and stroke volume (SV) were calculated from
standard formulas.
The physiological rationale for the calculation of PC
has been described in detail elsewhere (8). The PC and
RVSWI were calculated with the following formulas: PC
(ml/mm Hg) ¼ SV/pulmonary pulse pressure; and RVSWI
(gm$m/m2/beat) ¼ (mean PAP  mean RAP)  (cardiac
index/HR)  0.0136.
We included only patients who underwent repeat RHC
within 3 years of diagnostic catheterization to allow enough
time on therapy for pulmonary vascular and RV remodeling
while providing a relatively homogenous cohort with regard
to length of therapy. Pre- and post-treatment six minute
walk test distance (6MWD) and New York Heart Associ-
ation (NYHA) functional class were also recorded.
Statistical analysis. Continuous data are expressed as mean
 SD. The Mann-Whitney U or Kruskal-Wallis test wasused to compare differences in
continuous demographic, hemo-
dynamic, and outcome variables,
depending on the number of
groups. Paired measurements of
RVSWI and PC were compared
with the Wilcoxon signed rank
test. Categorical clinical and de-
mographic variables were com-
pared between groups with the
chi-square test. Spearman cor-
relation was used to show the
relationship between continuous
variables. A p value of <0.05 was
considered statistically signiﬁ-
cant. Statistical analyses were
performed with Prism software
(version 5.0, Graph Pad Soft-
ware, Inc., La Jolla, California)
and SPSS software (version 20,
SPSS, Inc., Chicago, Illinois).Results
Demographic and clinical
characteristics. At the time of
analysis, the VPHRC contained
616 unique cases, 183 of whom
were seen at Vanderbilt, treat-
ment-naïve, and had diagnostic
and repeat RHC data available.
Of those, 70 patients had a repeat
RHC within 3 years of diagnostic catheterization during the
time frame of the study; 12 of those 70 patients had either
incomplete RHC data (n¼ 4) or PWP>15 mmHg (n¼ 8).
Fifty-eight patients were included in the analysis representing
3 subtypes: IPAH (n ¼ 33), FPAH (n ¼ 16), and connective
tissue-associated PAH (n ¼ 9).
Demographic and clinical characteristics of the 58 study
patients divided into treatment regimen are shown in
Table 1. The distribution of baseline RVSWI is shown in
Figure 1. At the time of presentation, most patients (40 of
58, 69%) had supra-normal RVSWI, whereas 18 of 58
(31%) fell into the low or normal range.
Demographic data and clinical characteristics of the
cohort divided into tertiles of baseline RV function are
shown in Table 2. No differences in age or subtype of PAH
were found among the tertiles. However, the lowest tertile
contained a higher proportion of men compared with the
other tertiles (p ¼ 0.037). There was a strong trend toward
better functional class in the tertile with the highest RVSWI
(p ¼ 0.07).
Medical therapy and hemodynamic status. The median
time from starting medical therapy to the ﬁrst follow-up clinic
visit was 2.7 months (interquartile range 1.9 to 5.2 months).
The median time between diagnostic and repeat RHC was
Table 1 Demographic and Clinical Characteristics by Therapy
Oral Only
(n ¼ 17)
Prostanoid Only
(n ¼ 21)
Mixed Therapy
(n ¼ 7)
Vasodilator Responsive
(n ¼ 7) p Value
Age (yrs) 47.3  14.2 36.4  14.1 43.0  15.1 47.9  14.7 0.11
Female (%) 88 76 100 86 0.55
NYHA functional
class
2.1  0.6 2.1  1.0 2.0  0.8 1.9  0.9 0.94
6MWD (m) 387  111 370  117 321  136 377  93 0.59
BMI (kg/m2) 33.6  12.1 30.1  7.3 33.0  7.8 35.5  11.9 0.70
Medical therapy n/a
Epoprostenol
(ng/kg/min)
0 86 (11–30) 57 (14.2–30) 0
Treprostinil
(IV or inhaled)
(mg/kg/min)
0 14 (12.5–100) 43 (14–28) 0
Ambrisentan
(mg/day)
18 (5) 0 0 0
Bosentan
(mg/day)
35 (250) 0 14 (250) 0
Sildenaﬁl
(mg/day)
47 (38–150) 0 86 (60–150) 0
Tadalaﬁl
(mg/day)
12 (40) 0 0 0
Amlodipine
(mg/day)
18 (5–10) 0 0 42 (5–10)
Diltiazem
(mg/day)
12 (180–360) 0 0 29 (240–360)
Nifedipine
(mg/day)
0 0 0 29 (30–120)
Adjuvant therapy
Furosemide
(mg/day)
64 (20–160) 66 (20–160) 86 (20–160) 71 (20–160) 0.77
Oxygen
(l/min)
6 (2) 24 (2–4) 29 (2–3) 14 (2) 0.42
Warfarin
(mg/day)
47 (2.5–7.5) 76 (1.25–11) 49 (4–7.5) 49 (5–9) 0.17
Values are mean  SD, %, or % (dose range).
BMI ¼ body mass index; IV ¼ intravenous; NYHA ¼ New York Heart Association functional class; WHO ¼ World Health Organization; 6MWD ¼
6-minute walk distance.
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Seventeen patients were started on a regimen of oral therapy
(monotherapy or any combination), and 21 patients were
started on a regimen of prostanoid (intravenous or inhaled)
therapy. Seven patients were started on a regimen of com-
bination oral and prostanoid therapy, and an additional 7
patients were found to be vasodilator responsive and started
on a regimen of calcium channel blockers; 6 patients were not
started on a regimen of therapy, due to patient or physician
preference.
Hemodynamic data at the time of diagnostic catheteri-
zation according to treatment regimen are shown in Table 3.
The only difference among treatment groups was lower
mixed venous oxygen saturation in the prostanoid group
compared with the oral therapy group (58.2  10.7 vs. 66.6
 5.6, respectively; p ¼ 0.01). For the entire cohort, we
found a signiﬁcant increase in RVSWI (mean increase 3.4
9.5 gm$m/m2/beat, p ¼ 0.007) and PC (mean increase 0.4
 1.0 ml/mm Hg, p ¼ 0.02) after medical therapy (Fig. 2).
In the prostanoid group there was a signiﬁcant increase in
RVSWI (p ¼ 0.04) and a trend toward improvement in PC(p¼ 0.06). However, in the 17 patients started on a regimen
of oral therapy, neither RVSWI nor PC increased signiﬁ-
cantly after treatment (p ¼ 0.25 and 0.46, respectively)
(Fig. 3). In the 7 patients who were treated with calcium
channel blockers, RVSWI (15.7  4.0 gm$m/m2/beat vs.
19.4 3.2 gm$m/m2/beat; p¼ 0.02) and PC (1.2 0.3 ml/
mm Hg vs. 2.3  1.1 ml/mm Hg; p ¼ 0.03) both increased
after therapy.
Because only prostanoids and calcium channel blockers
were available between 1996 and 2001, we repeated our
analysis with a cutoff diagnosis date of January 2001 (n¼ 50).
Improvement in RVSWI and PC remained signiﬁcant in the
prostanoid group (p¼ 0.04 and 0.01, respectively) and did not
reach signiﬁcance in the oral therapy group (p ¼ 0.23 and
0.30, respectively).
Determinants of RV function. Change in RVSWI after
therapy was driven more by change in CO (rs ¼ 0.5,
p ¼ 0.002) than change in mPAP (rs ¼ 0.36, p ¼ 0.03)
(Figs. 4A and 4B). The major determinant of RVSWI
was change in SV (rs ¼ 0.54, p < 0.001). Increase in CO
after therapy was almost entirely due to an increase in SV
Figure 1 Distribution of Baseline RVSWI
Most patients (69%) had supra-normal right ventricular stroke work index (RVSWI)
at the time of diagnosis indicating right ventricular compensation in the setting of
elevated afterload.
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303(rs ¼ 0.89, p < 0.001) with no contribution from change in
HR (rs ¼ 0.1, p ¼ 0.3) (Figs. 4C and 4D). We found that
change in PC was strongly inﬂuenced by change in PVR
(rs ¼ 0.6, p < 0.001) (Fig. 5).
Change in PVR was investigated as a possible explanation
for the difference in RV function response between oral and
prostanoid therapy groups. We found no difference in
delta PVR between the oral-only and prostanoid groups
(0.4  4.6 WU vs. 4.5  7.9 WU, respectively;
p ¼ 0.07), although there was a strong trend toward
statistical signiﬁcance. Change in PVR and change in
RVSWI did not correlate signiﬁcantly in either the oral only
(rs ¼ 0.12, p ¼ 0.66) or prostanoid group (rs ¼ 0.20,
p ¼ 0.44).
When comparing the response to therapy by RVSWI
tertile, we found a stepwise response with the highest
improvement in RVSWI in the lowest tertile (Fig. 6). ThereTable 2 Demographic and Clinical Characteristics
Lowest Tertile
(n ¼ 19)
Midd
(n
Age at diagnosis 42.0  15.5 41.5
Female (%) 12 (63) 19
Diagnosis
IPAH 10 (53) 12
HPAH 8 (42) 4
CTD-PAH 1 (5) 4
Functional class 2.2  0.9 2.4
6MWD (m) 361  125 337
Diabetes (%) 5 (26) 6
BMI (kg/m2) 31.4  7.0 33.3
Values are mean  SD or n (%).
CTD-PAH ¼ connective tissue disease-associated pulmonary arterial hype
idiopathic pulmonary arterial hypertension; RVSWI ¼ right ventricular strokewas no association between tertile of baseline RVSWI and
likelihood of being treated with prostanoid therapy
(p ¼ 0.67; 95% conﬁdence interval: 0.4 to 1.7). A similar
stepwise pattern in PC was seen in response to therapy with
the lowest baseline tertile improving the most (Fig. 6).
Outcomes. Differences in change in 6MWD and func-
tional class by group are shown in Table 4. Improvement in
both 6MWD and functional class was signiﬁcantly better in
the prostanoid group, compared with the oral therapy group.
For the cohort as a whole, no correlation was found between
RVSWI at diagnosis and 6MWD (rs ¼ 0.08, p ¼ 0.59) or
functional class (rs ¼ 0.19, p ¼ 0.16) at diagnosis,
although improvement in RVSWI (net increase 3.4  9.5
gm-m/m2/beat) was associated with improvement in both
functional class (net decrease 0.8  0.8; rs ¼ 0.32,
p¼ 0.016) and change in 6MWD (net increase 46 103 m;
rs ¼ 0.52, p ¼ 0.04) at ﬁrst follow-up visit after initiation
of therapy. Change in SV was an independent predictor of
improvement in functional class when controlling for mPAP
and HR with an odds ratio of 1.04/ml (p ¼ 0.03; 95%
conﬁdence interval: 1.004 to 1.09).
Discussion
In this study of 58 mixed-etiology PAH patients, we report
the response of RV function and PC before and after PAH-
speciﬁc therapy. For the entire cohort, we found that im-
provement in RV function was driven by patients treated with
prostanoid therapy. Patients with the poorest baseline RV
function had the greatest improvement post-therapy, a ﬁnding
that might have implications for identifying patients with the
greatest potential beneﬁt from therapy. Improvement in PC
was limited to patients treated with prostanoid therapy and
vasodilator-responsive patients treated with calcium channel
blockers. Finally, we showed that improvement in RVSWI
predicts improvement in post-therapy 6MWD and functional
class.
The RVSWI is a measure of RV function that can be readily
calculated from the usual components of a diagnostic RHC. It
is used clinically in patients with LV failure, but little is knownby Tertile of RVSWI
le Tertile
¼ 20)
Highest Tertile
(n ¼ 19) p Value
 13.5 43.5  15.6 0.94
(95) 16 (84) 0.04
0.38
(60) 11 (58)
(20) 4 (21)
(20) 4 (21)
 0.8 1.8  0.6 0.07
 126 330  98 0.56
(30) 6 (26) 0.96
 13.1 30.1  9.2 0.66
rtension; HPAH ¼ heritable pulmonary arterial hypertension; IPAH ¼
work index; 6MWD ¼ 6-minute walk distance.
Table 3 Hemodynamic Status at Diagnosis by Therapy
Parameter Prostanoid Only Oral Only Mixed Therapy Vasodilator Responsive p Value
HR (beats/min) 80.8  11.7 77.0  10.1 81.4  6.1 77.3  9.1 0.76
Mean RAP (mm Hg) 9.6  6.8 7.3  6.2 7.7  5.6 7.3  3.3 0.69
PA systolic pressure
(mm Hg)
82.4  18.5 81.9  20.3 75.3  14.1 80.1  14.1 0.91
Mean PA pressure (mm Hg) 54.5  12.6 49.8  11.0 48.3  9.5 47.7  9.3 0.49
PWP (mm Hg) 8.8  2.5 7.8  3.6 9.5  3.6 8.3  3.7 0.85
Pulmonary vascular resistance
(WU)
13.6  7.7 9.7  2.8 10.0  3.3 10.0  2.6 0.49
Cardiac index (l/min/m2) 2.0  0.6 2.2  0.3 2.0  0.8 2.2  0.5 0.28
Mixed venous oxygen
saturation (%)
58.2  10.7* 66.6  5.6 57.2  9.7y 63.7  9.4 0.04
RVSWI (gm$m/m2/beat) 14.8  5.0 17.1  5.6 15.8  8.9 15.7  4.0 0.63
PC (ml/mm Hg) 1.2  0.6 1.2  0.3 1.2  0.5 1.2  0.3 0.98
Values are mean  SD. *p ¼ 0.01 for prostanoid vs. oral therapy group. yn ¼ 5.
HR ¼ heart rate; PA ¼ pulmonary artery; PC ¼ pulmonary capacitance; PWP ¼ pulmonary wedge pressure; RAP ¼ right atrial pressure; RVSWI ¼
right ventricular stroke work index; WU ¼ Wood units.
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304about its natural history or ability to prognosticate in patients
with PAH (12). We previously showed that, as judged by
RVSWI, FPAH patients are less compensated at the time of
diagnosis, comparedwith IPAHpatients. In addition,RVSWI
is lower in FPAH patients who die or undergo lung transplant
within 5 years of diagnosis (9). In our cohort, most patients
(69%) had supra-normal RVSWI at baseline, despite limited
functional capacity measured by NYHA functional class and
exercise capacity. This discrepancy might be explained by the
subjective nature of NYHA functional class and variations in
effort on 6MWtesting, particularly in relation to obese patients
as in our cohort (13,14).
To better understand why RVSWI changes in response to
therapy, we analyzed the relationship between individual
components (mPAP and CO) and the composite parameter.
The CO had a stronger inﬂuence than mPAP in the
response of RVSWI to PAH therapy, but both components
provided a signiﬁcant inﬂuence. Change in CO was almost
entirely driven by improvement in SV, supporting our
hypothesis that improvement in RVSWI in response to
therapy is due to improved RV contractility, not increase inFigure 2 RVSWI and PC Improve After PAH Therapy
Right ventricular stroke work index (RVSWI) and pulmonary capacitance (PC) increase afte
mean  SD.HR. The importance of RV function in PAH is further
supported in our study by the independent value of SV in
predicting improvement in functional class. The RVSWI
might be superior to either CO or mPAP alone and might
have a previously unrecognized role to play in the interpre-
tation of invasive hemodynamic status in PAH.
Little is known about the response to therapy of RV
function in PAH. Although RVSWI and PC increased
post-therapy in the cohort as a whole, this ﬁnding was
driven by an increase in RVSWI and PC in the 21 patients
started on a regimen of prostanoid only therapy. Potential
explanations for this difference include greater efﬁcacy of
prostanoids in therapy of PAH pulmonary vascular disease,
a direct effect of prostaglandins on the RV (15,16), or
differences in treatment as a function of disease severity
reﬂected in RVSWI or other unfavorable hemodynamic
predictors. The strong inﬂuence we found of SV on change
in RVSWI suggests that prostanoids might exert an
inotropic effect on the RV, but this requires further study.
Patients in the lowest tertile at diagnosis had the greatest
improvement in RVSWI after treatment, reﬂecting the well-r administration of pulmonary arterial hypertension–speciﬁc therapy. Bars represent
Figure 4 Determinants of Response of RVSWI to Therapy
Change in right ventricular stroke work index (RVSWI) after therapy is strongly inﬂuenced by change in cardiac output with less contribution from change in mean pulmonary artery
pressure (A, B). Improvement in cardiac output after therapy is due to change in stroke volume with no inﬂuence from change in heart rate (C, D). Solid line represents best-ﬁt
line; dashed lines are 95% conﬁdence interval.
Figure 3 Effect of Prostanoid or Oral Therapy on RVSWI and PC
Right ventricular function improves after treatment with prostanoids but not after therapy with oral pulmonary arterial hypertension medications. There is a trend toward
improvement in pulmonary capacitance (PC) with prostanoids and no improvement after oral therapy. Epo = prostanoid; RVSWI ¼ right ventricular stroke work index.
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Figure 5
PC Is a Measure of Pulmonary Vascular Resistance in
Patients With PAH
In patients with pulmonary arterial hypertension (PAH), change in pulmonary
capacitance (PC) after therapy is primarily inﬂuenced by change in pulmonary
vascular resistance. Solid line represents best-ﬁt line; dashed lines are 95%
conﬁdence interval. WU ¼ Wood unit.
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306described ability of the RV to recover function with removal of
load stress (17,18). Although signs and symptoms of RV
dysfunction at diagnosis are often recognized by treating
physicians, quantiﬁcation of low RVSWI at diagnosis might
help clinicians identify patients at risk for poor outcomes and
the greatest potential beneﬁt from aggressive therapy.
Pulmonary capacitance measures the ability of the
pulmonary vasculature to receive blood during RV systole
and then expel blood from the pulmonary tree during
diastole. In the normal pulmonary circulation, resistance is
nearly 0 (1 WU), and therefore elastic recoil is primarily
responsible for capacitance. In contrast, in PAH, there is
reduction in lumen size, dropout of vessels, and thickening
of large arteries such that compliance is low, and PVR
probably accounts for most of capacitance data. This is
supported by our data showing that PVR has a strongFigure 6 RVSWI and PC at the Time of Diagnosis Predict Hemodyna
Right ventricular stroke work index (RVSWI) and pulmonary capacitance (PC) change in a s
the lowest baseline tertiles. Bars represent mean  SD. PAH ¼ pulmonary arterial hyperinverse association with PC in our cohort. The prognostic
value of PC, measured at RHC or echocardiography, in
patients with IPAH is well-described (8,19). However, the
response of PC to PAH therapy has not previously been
studied. The increase in PC after therapy in our study was
driven by the presence of prostanoids in the treatment
regimen (either alone or in combination with oral therapy).
In patients with PAH, a decrease in PVR is thought to
drive improvement in RV function by decreasing RV
afterload; however, improvement or decline in RV function
is often independent of the change in PVR after therapy (3).
This is supported by our ﬁnding of no difference in change
in PVR between patients with oral-only regimens and those
treated with prostanoids; however, our study might have
been underpowered to detect this difference, given that the p
value was nearly signiﬁcant (p ¼ 0.07). Tedford et al. (20)
recently showed that the inﬂuence of PVR on RV after-
load is governed by the hyperbolic relationship between
PVR and PC. The ﬁxed relationship between PVR and PC
and the ﬂatness of the curve at elevated PVR means that
patients with high baseline PVR require signiﬁcant decreases
in PVR (not often produced with current PAH therapy) to
achieve a decrease in RV afterload. Thus, our ﬁndings
suggest that improvement in RV function on a regimen of
prostanoid therapy might represent a direct effect on RV
contractility, not simply a decrease in resistance.
Study limitations. Our study has a relatively small sample
size, compared with contemporary studies of hemodynamic
variables in PAH, but it is the ﬁrst to report the response of
RVSWI and PC to therapy. Patients who died or were lost
from the study before follow-up catheterization were
excluded from this analysis, which might limit the prog-
nostic value of our ﬁndings and bias to the null hypothesis.
The RVSWI is an imperfect measure of RV function and
reﬂects inﬂuences from both afterload and preload.
However, it is used clinically in patients with left heart
disease and has prognostic value in patients with PAH
(9,21). In addition, our detailed analysis suggests that itmic Response to PAH Therapy
tep-wise fashion after therapy with the greatest improvement found in the patients in
tension.
Table 4 Outcome Differences Among Treatment Groups
Outcome
Prostanoid
(n ¼ 21)
Oral
(n ¼ 17)
Mixed Therapy
(n ¼ 7)
Vasodilator Responsive
(n ¼ 7) p Value
Delta 6MWD 124  106* 4  109 40  57 32  35 0.013
Delta functional class 1.3  0.6y 0.5  0.5 0.7  0.8 1.0  0.8 0.001
Negative value indicates improvement in functional class. *p ¼ 0.006 vs. oral therapy group. yp < 0.001.
6MWD ¼ 6-minute walk distance.
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307might add incremental value to interpretation of its indi-
vidual components. Echocardiographic data would have
provided an additional measure of RV function but were not
available for analysis in our cohort over the extended period
of the study.
Conclusions
In this study of serial hemodynamic measurements in patients
with PAH we have shown that RV function improves after
prostanoid therapy but not after therapy with oral medica-
tions. Patients with the least compensated RV function at
diagnosis had the greatest post-therapy improvement in RV
function and might derive the most beneﬁt from therapy.
Larger studies are needed to validate these ﬁndings and
determine the clinical utility of RVSWI and PC versus
conventional hemodynamic parameters. Further study is also
needed to explore the potential of prostanoid therapy to
directly improve RV function.
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